Logo image of MNPR

MONOPAR THERAPEUTICS INC (MNPR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MNPR - US61023L2079 - Common Stock

75.91 USD
+1.3 (+1.75%)
Last: 12/15/2025, 2:10:36 PM
Fundamental Rating

3

Taking everything into account, MNPR scores 3 out of 10 in our fundamental rating. MNPR was compared to 529 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MNPR as it has an excellent financial health rating, but there are worries on the profitability. MNPR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MNPR had negative earnings in the past year.
In the past year MNPR has reported a negative cash flow from operations.
MNPR had negative earnings in each of the past 5 years.
In the past 5 years MNPR always reported negative operating cash flow.
MNPR Yearly Net Income VS EBIT VS OCF VS FCFMNPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

MNPR's Return On Assets of -13.48% is amongst the best of the industry. MNPR outperforms 81.29% of its industry peers.
MNPR's Return On Equity of -13.73% is amongst the best of the industry. MNPR outperforms 86.58% of its industry peers.
Industry RankSector Rank
ROA -13.48%
ROE -13.73%
ROIC N/A
ROA(3y)-73.47%
ROA(5y)-60.42%
ROE(3y)-94.55%
ROE(5y)-74.37%
ROIC(3y)N/A
ROIC(5y)N/A
MNPR Yearly ROA, ROE, ROICMNPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

MNPR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNPR Yearly Profit, Operating, Gross MarginsMNPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

9

2. Health

2.1 Basic Checks

MNPR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MNPR has been reduced compared to 5 years ago.
MNPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MNPR Yearly Shares OutstandingMNPR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MNPR Yearly Total Debt VS Total AssetsMNPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

MNPR has an Altman-Z score of 113.15. This indicates that MNPR is financially healthy and has little risk of bankruptcy at the moment.
MNPR has a Altman-Z score of 113.15. This is amongst the best in the industry. MNPR outperforms 99.24% of its industry peers.
MNPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 113.15
ROIC/WACCN/A
WACCN/A
MNPR Yearly LT Debt VS Equity VS FCFMNPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

MNPR has a Current Ratio of 56.10. This indicates that MNPR is financially healthy and has no problem in meeting its short term obligations.
MNPR has a Current ratio of 56.10. This is amongst the best in the industry. MNPR outperforms 99.43% of its industry peers.
MNPR has a Quick Ratio of 56.10. This indicates that MNPR is financially healthy and has no problem in meeting its short term obligations.
MNPR has a better Quick ratio (56.10) than 99.43% of its industry peers.
Industry RankSector Rank
Current Ratio 56.1
Quick Ratio 56.1
MNPR Yearly Current Assets VS Current LiabilitesMNPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MNPR have decreased strongly by -101.02% in the last year.
EPS 1Y (TTM)-101.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MNPR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.05% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.66%
EPS Next 2Y4.34%
EPS Next 3Y5.75%
EPS Next 5Y12.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNPR Yearly Revenue VS EstimatesMNPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
MNPR Yearly EPS VS EstimatesMNPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MNPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MNPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNPR Price Earnings VS Forward Price EarningsMNPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNPR Per share dataMNPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.34%
EPS Next 3Y5.75%

More info and screens

0

5. Dividend

5.1 Amount

MNPR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MONOPAR THERAPEUTICS INC

NASDAQ:MNPR (12/15/2025, 2:10:36 PM)

75.91

+1.3 (+1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)03-30 2026-03-30/amc
Inst Owners65%
Inst Owner Change37.64%
Ins Owners4.72%
Ins Owner Change-108.21%
Market Cap507.08M
Revenue(TTM)N/A
Net Income(TTM)-19.44M
Analysts84.21
Price Target114.01 (50.19%)
Short Float %7.29%
Short Ratio3.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.93%
Min EPS beat(2)-9.44%
Max EPS beat(2)27.3%
EPS beat(4)2
Avg EPS beat(4)-119.71%
Min EPS beat(4)-541.92%
Max EPS beat(4)45.21%
EPS beat(8)5
Avg EPS beat(8)-52.2%
EPS beat(12)8
Avg EPS beat(12)-31.46%
EPS beat(16)10
Avg EPS beat(16)-22.47%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.17%
PT rev (3m)35.89%
EPS NQ rev (1m)11.94%
EPS NQ rev (3m)23.32%
EPS NY rev (1m)1.25%
EPS NY rev (3m)7.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.58
P/tB 3.58
EV/EBITDA N/A
EPS(TTM)-3.96
EYN/A
EPS(NY)-3.75
Fwd EYN/A
FCF(TTM)-1.62
FCFYN/A
OCF(TTM)-1.62
OCFYN/A
SpS0
BVpS21.19
TBVpS21.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.48%
ROE -13.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.47%
ROA(5y)-60.42%
ROE(3y)-94.55%
ROE(5y)-74.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 56.1
Quick Ratio 56.1
Altman-Z 113.15
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-101.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.73%
EPS Next Y58.66%
EPS Next 2Y4.34%
EPS Next 3Y5.75%
EPS Next 5Y12.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-209.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-95.03%
EBIT Next 3Y-45.26%
EBIT Next 5YN/A
FCF growth 1Y-42.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.25%
OCF growth 3YN/A
OCF growth 5YN/A

MONOPAR THERAPEUTICS INC / MNPR FAQ

What is the ChartMill fundamental rating of MONOPAR THERAPEUTICS INC (MNPR) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MNPR.


What is the valuation status for MNPR stock?

ChartMill assigns a valuation rating of 0 / 10 to MONOPAR THERAPEUTICS INC (MNPR). This can be considered as Overvalued.


What is the profitability of MNPR stock?

MONOPAR THERAPEUTICS INC (MNPR) has a profitability rating of 2 / 10.


What is the financial health of MONOPAR THERAPEUTICS INC (MNPR) stock?

The financial health rating of MONOPAR THERAPEUTICS INC (MNPR) is 9 / 10.